This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vicarious Surgical (RBOT) Partners LSU Health New Orleans
by Zacks Equity Research
Vicarious Surgical (RBOT) teams up with LSU Health New Orleans to advance its V1.0 surgical robot. It aims to file for FDA approval by 2026.
Smith & Nephew (SNN), HOPCo to Enhance Musculoskeletal Care
by Zacks Equity Research
Smith & Nephew (SNN) announces a collaboration with HOPCo to focus on enhancing solutions for ASC customers, physicians, and patients through the latter's digital health and analytics platforms.
Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Inogen's (INGN) second-quarter 2024 results reflect significant improvement in the top and bottom lines, driven by strong international and domestic business-to-business sales.
Inspire Medical (INSP) Q2 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Inspire Medical (INSP) reports strong second-quarter results, reflecting a 30% revenue increase. Its new technology and expanded U.S. presence promise growth and enhanced patient care.
Limbach (LMB) Tops Q2 Earnings Estimates
by Zacks Equity Research
Limbach (LMB) delivered earnings and revenue surprises of 35.14% and 1.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Completes MOLLI's Acquisition to Boost Business
by Zacks Equity Research
Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.
CooperCompanies (COO) Acquires obp Surgical to Boost Portfolio
by Zacks Equity Research
CooperSurgical, a unit of CooperCompanies (COO), acquires obp Surgical for $100 million, adding innovative single-use surgical retractors and suction devices to its portfolio.
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics
by Zacks Equity Research
Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.
Inspire Medical (INSP) Gets FDA Nod for Inspire V System
by Zacks Equity Research
Inspire Medical (INSP) secures FDA approval for its advanced Inspire V therapy system, featuring an innovative neurostimulator and Bluetooth technology for enhanced patient and physician control.
Is Charles River Associates (CRAI) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how CRA International (CRAI) and ABM Industries (ABM) have performed compared to their sector so far this year.
Ecolab (ECL) Sells Surgical Solutions Business to Medline
by Zacks Equity Research
Ecolab's (ECL) deal to sell its global surgical solutions business to Medline enables it to focus on infection prevention and instrument reprocessing while enhancing shareholders' returns.
CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
by Zacks Equity Research
CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.
Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.
Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines
by Zacks Equity Research
Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline. Operating margin contracts.
Are Investors Undervaluing ABM Industries (ABM) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.
Republic Services (RSG) Earnings Surpass Estimates in Q2
by Zacks Equity Research
Republic Services' (RSG) top and bottom lines increase year over year in second-quarter 2024.
Is the Options Market Predicting a Spike in ABM Industries (ABM) Stock?
by Zacks Equity Research
Investors need to pay close attention to ABM Industries (ABM) stock based on the movements in the options market lately.
Is S&P Global (SPGI) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how S&P Global (SPGI) and ABM Industries (ABM) have performed compared to their sector so far this year.
ABM Industries (ABM) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
ABM Industries (ABM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy ABM Industries (ABM) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Broker-Loved Stocks to Keep an Eye on in the Current Scenario
by Maharathi Basu
Investors would do well to keep a tab on stocks like Air Transport Services (ATSG), Allegiant Travel (ALGT), ABM Industries (ABM), American Axle (AXL) and Warner Bros. (WBD).
ABM Industries (ABM) Stock Rises 22.5% in a Year: Here's How
by Zacks Equity Research
ABM Industries' (ABM) multi-year comprehensive strategic plan, ELEVATE, focuses on providing clients with offerings that enhance transparency and efficiencies.
Accenture (ACN) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Accenture's (ACN) third-quarter fiscal 2024 revenues and earnings are expected to have declined year over year.
4 Broker-Favorite Stocks to Monitor Post Analyst Upgrades
by Maharathi Basu
Investors would do well to keep a tab on stocks like Bread Financial (BFH), ABM Industries (ABM), Centene (CNC) and AdvanSix (ASIX).